Since the company's clinical data mix-up in a non-small-cell lung cancer study of bavituximab, Peregrine investors have been anxiously waiting to see what, if any, life might remain for the drug in this potentially lucrative indication. Today, the company released interim findings from its investigation into the mishap, and, as one might expect to see from a company with its back against the wall, the findings were considered positive. However, as Brenton Flynn discusses in the following video, investor should approach this with a "once bitten, twice shy" mentality.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Up 70%, Peregrine's Clinical Lemon Becomes Lemonade
Turning clinical data lemons into lemonade.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.